IRD Opus Genetics, Inc.

IRD financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 1228627 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 10, 2026 Data checked: Nov 13, 2026
Showing 3 of 24 annual and 0 of 65 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$45.90M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
(984) 884-6030
EIN
113516358
Headquarters
DURHAM, NC, 27713
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: Ocuphire Pharma, Inc. (2020–2024) · REXAHN PHARMACEUTICALS, INC. (2005–2020) · CORPORATE ROAD SHOW DOT COM INC (2003–2005) · FERRARO FRANK (2003–2003)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
$7.91M
Net Income
$-136.65M
Total Assets
$95.30M
Total Equity
$38.43M
Total Debt
-
Free Cash Flow
-
Ratios
Operating Margin
-777.7%
Net Margin
-1726.7%
Return on Equity
-355.6%
Return on Assets
-143.4%
Current Ratio
9.65x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

In fiscal 2025, Opus Genetics, Inc. recorded $14.20M of revenue, net loss of $49.59M, and an operating cash outflow of $35.25M. The $14.20M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The top line expanded 29.1% from $10.99M in fiscal 2024, increasing the company’s operating scale. The company reported diluted EPS of -$0.80, adding a shareholder-level measure to the absolute income figures considered below. A diluted share base of 62.22M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Diluted shares moved 132.9% from 26.72M in fiscal 2024, leaving the current share base higher year over year. At period end, total assets were $50.24M, framing the scale of the company’s operating and financing commitments. Asset turnover was 0.28x, relating the company’s annual revenue directly to the total assets reported at the period end.

Profitability

The company recorded an operating loss of $38.60M after the reported operating expense base. Relative to revenue, the operating deficit measured 271.9%, showing the shortfall after operating costs. After all below-operating-line items, the company recorded a net loss of $49.59M for the fiscal year. Measured against revenue, the bottom-line deficit represented 349.3% after all recognized items. The company reported negative EBITDA of $38.55M, adding a pre-interest, tax, depreciation, and amortization view of the operating shortfall. The company reported a pretax loss of $49.59M, before the effect of income taxes. Pretax margin was -349.3%, reflecting a pre-tax loss equal to 349.3% of revenue. Income tax expense totaled $0.00, providing the reported tax component that separates pretax and after-tax earnings. The loss-to-equity relationship was 323.1%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 98.7%. The bottom-line deficit decreased from $57.53M in fiscal 2024 to $49.59M.

Liquidity and Capital Structure

At period end, the $50.24M asset base was financed through $34.90M of liabilities and $15.35M of equity. Current assets were $50.04M against $7.78M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 6.43x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. The company held $45.09M in cash and equivalents, a narrower liquidity measure than total current assets. Measured only with cash and equivalents, coverage of current liabilities was 579.5%, excluding receivables and other current assets. Borrowings totaled $1.13M, adding a fixed financing obligation alongside the company’s equity capital. Debt equaled 0.07x of book equity, describing the relative scale of borrowing and shareholder capital. Relative to total assets, debt measured 2.2%, showing how much of the asset base was matched by borrowing. Book equity represented 30.5% of total assets, quantifying the balance-sheet share supported by shareholder capital. Relative to total assets, liabilities measured 69.5%, complementing the separate equity-based view of the company’s capital structure. Measured against total assets, cash and equivalents represented 89.7%, a balance-sheet composition measure rather than a liquidity forecast. Compared with $36.86M in fiscal 2024, the current asset base moved 36.3% and finished higher. Reported equity changed 128.3% from $6.72M in fiscal 2024, placing the current capital base higher year over year. The reported cash balance changed 48.7% from $30.32M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $35.25M, showing that operations absorbed cash during the period. Cash absorbed by operations increased from $25.58M in fiscal 2024 to $35.25M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for Opus Genetics, Inc.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue $14.20M $10.99M $19.05M
OPERATING EXPENSES
R&D Expense $30.81M $26.85M $17.65M
SG&A Expense $21.98M $18.22M $11.96M
Operating Income $-38.60M $-62.07M $-10.56M
NON-OPERATING INCOME / EXPENSE
Interest Expense - - $0
Other Income/Expense $1.99M $4.47M $1.84M
Pretax Income $-49.59M $-57.53M $-9.97M
Income Tax $0 $0 $12.00K
Net Income $-49.59M $-57.53M $-9.99M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-0.80 $-2.15 $-0.46
Diluted Shares 62.22M 26.72M 21.59M
EBITDA $-38.55M $-62.06M $-10.56M
Depreciation & Amortization $53.00K $10.00K $6.00K
Balance Sheet
ASSETS
Cash & Equivalents $45.09M $30.32M $50.50M
Short-term Investments $0 $2.00K $15.00K
Accounts Receivable $2.00M $3.56M $926.00K
Other Current Assets $1.79M $515.00K $1.10M
Current Assets $50.04M $36.61M $53.95M
PP&E (Net) $199.00K $252.00K $0
Noncurrent Assets $199.00K $252.00K $0
Total Assets $50.24M $36.86M $53.95M
LIABILITIES
Accounts Payable $3.29M $3.15M $2.15M
Other Current Liabilities $15.00K $606.00K $71.00K
Current Liabilities $7.78M $11.30M $4.04M
Long-term Debt $1.13M $0 -
Other Noncurrent Liabilities (derived) $25.99M $0 -
Noncurrent Liabilities $27.11M $0 $0
Total Liabilities $34.90M $11.30M $4.04M
EQUITY
Common Stock $7.00K $3.00K $2.00K
Additional Paid-in Capital $203.93M $145.72M $131.37M
Retained Earnings $-188.59M $-139.00M $-81.47M
Total Equity $15.35M $6.72M $49.91M
Temporary Equity $0 $18.84M $0
Total Liabilities & Equity $50.24M $36.86M $53.95M
SUPPLEMENTAL
Shares Outstanding 69.89M 31.57M 23.98M
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-35.25M $-25.58M $-1.11M
Capital Expenditures - - -
Cash from Investing $0 $1.21M $0
Cash from Financing $50.02M $4.19M $8.98M
Free Cash Flow - - -
Beginning Cash (CFS) $30.32M $50.50M $42.63M
Net Change in Cash $14.77M $-20.18M $7.87M
Effect of FX on Cash - - -
Calculated Ending Cash $45.09M $30.32M $50.50M
Cash per BS $45.09M $30.32M $50.50M
Cash scope difference (CFS − BS) - - -
Cash per CFS $45.09M $30.32M $50.50M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

What is Opus Genetics, Inc.'s annual revenue?

Opus Genetics, Inc. reported $7.91M in revenue for trailing twelve months (ending September 2026). Revenue figures are sourced from the company's annual SEC EDGAR filing.

Is Opus Genetics, Inc. profitable?

No. Opus Genetics, Inc. reported $-136.65M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.